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Summary
DNA methylation studies have elucidated a methylation signature distinguishing primary 
melanomas from benign nevi and provided new insights about genes that may be important in 
melanoma development. However, it is unclear whether methylation differences among primary 
melanomas are related to tumor pathologic features with known clinical significance. We utilized 
the Illumina Golden Gate Cancer Panel array to investigate the methylation profiles of 47 primary 
cutaneous melanomas. Array-wide methylation patterns revealed a positive association of 
methylation with Breslow thickness and mutated BRAF, a negative association with mitotic rate, 
and a weak association with ulceration. Hierarchical clustering on CpG sites exhibiting the most 
variable methylation (n=235) divided the melanoma samples into three clusters, including a 
highly-methylated cluster that was positively associated with Breslow thickness and an 
intermediately-methylated cluster associated with Breslow thickness and mitotic rate. Our findings 
provide support for the existence of methylation-defined subsets in melanomas, with increased 
methylation associated with Breslow thickness.
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Introduction
Melanoma is an aggressive malignancy that can metastasize early. In addition to somatic 
mutations, epigenetic alterations are emerging as contributors to melanoma development, 
potential complementary diagnostic and prognostic biomarkers, and even novel targets for 
treatments(Greenberg et al., 2012; van den Hurk et al., 2012). The most studied epigenetic 
changes in melanoma involve hypermethylation at specific sites, commonly in CpG-rich 
regions of promoters (Hughes et al., 2013). Despite increasing knowledge about the impact 
of methylation in melanoma biology, little is known about the methylation profiles of 
primary melanoma specimens. Previously we elucidated methylation differences 
distinguishing primary melanomas from benign nevi (Conway et al., 2011), but it is unclear 
if aberrant methylation in melanoma is associated with worse prognostic characteristics or 
may define a clinically-relevant subtype. Characterizing the relationship between melanoma 
profiling and well established pathologic and molecular features could shed light on whether 
methylation has a role in melanoma progression and tumor heterogeneity. This knowledge 
could also impact selection of methylation markers for primary melanoma diagnostic and 
prognostic panels.
In other studies, global methylation profiling has associated CpG island methylation in 
melanoma with progression to brain metastasis(Marzese et al., 2013) and with worse 
prognosis in stage IIIC patients(Sigalotti et al., 2012). However, limited data has been 
reported on the association of methylation with melanoma pathologic features or molecular 
subtypes. NRAS-mutation has been associated with p16INK4A promoter methylation 
(Jonsson et al., 2010), and in vitro studies have indicated that BRAF mutation may play a 
role in regulating methylation in melanoma (Hou et al., 2012; Liu et al., 2012). However, an 
array-based investigation of 24 primary melanomas did not find methylation to be associated 
with either BRAF mutation status or mitotic rate(Gao et al., 2013). Similarly, no association 
between ulceration and methylation was observed in a set of 98 CpG sites in genes 
differentially expressed with ulceration in 17 primary melanomas (Rakosy et al., 2013). 
LINE-1 repeat sequences, which are hypomethylated in melanoma, have also not been 
shown to be associated with histopathologic factors (Hoshimoto et al., 2012). The finding 
that melanomas can lose the ability to convert 5-methylcytosine to 5-hydroxymethylcytosine 
(5-hmc), a first step in the demethylation process, supports a link between methylation and 
biologic features, as reduced 5-hmc has been associated with increased Breslow thickness, 
high mitotic rate, and ulceration in primary melanomas, as well as worse tumor stage and 
lower survival(Lian et al., 2012). Progressive loss of 5-hmc was also observed with 
increasing dysplasia in melanocytic tumors (Larson et al., 2014). In addition to relationships 
between methylation and pathologic features, the presence of a distinctly hypermethylated 
tumor subset in cell lines as well as primary and metastatic melanoma tissue has been 
suggested by studies showing aberrant hypermethylation at a limited number of gene 
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promoters and other loci(Tanemura et al., 2009; Tellez et al., 2009). This proposed CpG 
island methylator phenotype, or CIMP, has been associated with advancing AJCC 
(American Joint Committee on Cancer) TNM (tumor, regional nodes, distant 
metastasis)melanoma stage(Tanemura et al., 2009).
In order to investigate whether specific DNA methylation events were associated with tumor 
progression or subtype, we examined methylation at CpG sites in relation to pathologic 
features used for AJCC tumor staging(Balch et al., 2009)and tumor BRAF and NRAS 
mutation status in a clinically heterogeneous set of well-annotated primary melanomas. 
Using the Illumina Golden Gate Methylation Cancer Panel 1 array, which allowed for 
analysis of 1402 CpG sites after quality control filtering, we evaluated the methylation 
patterns among 47 primary cutaneous melanomas. We explored array-wide methylation 
patterns according to their associations with Breslow thickness, mitotic rate, ulceration, and 
tumor mutation status. Differential methylation at individual CpG sites was investigated 
using univariate and multivariate analyses. Then, in order to determine whether methylation 
profiles comprise distinct phenotypes, we employed unsupervised hierarchical clustering on 
the most variable CpGs (n = 235), followed by K means clustering. The resulting 
methylation-based clusters were then evaluated for associations with pathologic features and 
tumor mutational status as a first step towards investigating whether methylation may define 
a clinically relevant subtype.
Results
Melanoma patient and tumor characteristics
We utilized data from 47 formalin-fixed paraffin-embedded (FFPE) invasive cutaneous 
primary melanomas that had undergone DNA methylation profiling and passed filtering 
criteria using the Golden Gate array (Conway et al., 2011). Clinical and histologic 
characteristics (Table 1) included a median Breslow thickness of 3.1 mm (range 0.4–15.0) 
and a median mitotic rate of 1.0 mitoses/mm2 (range 0–9), with 38% ulcerated. BRAF or 
NRAS mutations were found in 43% and 11%, respectively, of the melanomas mutually 
exclusive of each other, while the remaining 47% had neither mutation (wildtype). As the 
group of NRAS mutated tumors alone (n = 5) was underpowered for analysis, we focused on 
BRAF mutated tumors. We found that the combined group of BRAF and NRAS mutated 
tumors did not change our analyses of mutational status; therefore, we report analyses of 
mutational status that include BRAF mutated and wildtype tumors only (n = 42).
Array-wide methylation patterns associated with pathologic characteristics
Locus by locus univariate analysis of pathologic covariates vs. CpG methylation at all 1402 
CpG sites revealed overall association patterns, which are displayed in volcano plots (Figure 
1A). Array-wide, Breslow thickness was positively associated with CpG methylation. 
Methylation levels were also higher in tumors harboring a BRAF mutation compared with 
wildtype. Mitotic rate showed a negative association with methylation, while ulceration was 
only weakly positively associated with methylation. A pairwise scatter plot of the 
coefficients for Breslow thickness vs. mitotic rate (Figure 1B) clarifies the opposite 
methylation trends associated with Breslow thickness and mitotic rate, showing that one 
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subset of CpGs (upper right quadrant) was significant for a positive association with 
Breslow thickness, while a different subset of CpGs (left lower quadrant) was significant for 
a negative association with mitotic rate. This shows that the observed methylation trends for 
Breslow thickness and mitotic rate were driven by different subsets of CpGs. Similarly, 
Breslow thickness, when compared to either ulceration or mutation, was characterized by 
largely different sets of CpGs, as were each of the other attributes when correlated against 
one another (data not shown). Breslow thickness and mitotic rate were the most correlated of 
the clinical attributes, with a rho 0.58. Breslow thickness vs. ulceration and mitotic rate vs. 
ulceration also showed moderate correlation, while the other plots showed weak correlation 
(data not shown).
CpG loci associated with pathologic characteristics
A limited number of individual CpG loci were found to have differential methylation that 
was significantly associated with pathologic characteristics in univariate and multivariate 
analyses. Reported here are CpG sites that were significant at FDR-adjusted q-value < 0.1; 
additional CpGs with an unadjusted p-value < 0.001 are listed in Table 2. In univariate 
analysis, methylation levels at four CpG sites were positively correlated with Breslow 
thickness (unadjusted r-values reported): PTK7_E317_F (r= 0.43), ABCB4_E429_F (r= 
0.37), HOXA9_P303F (r= 0.61), and IRAK3_P185_F (r= 0.51). The former three remained 
significant in multivariate analysis. MMP14_P208_R was negatively correlated with mitotic 
rate (r=−0.26) in multivariate analysis only. KLK10_P268_R was positively associated with 
BRAF mutation in univariate analysis only (mean β-value +0.35 in tumors with BRAF 
mutation vs. wildtype). No CpG sites were significantly associated with ulceration.
Validation
Technical validation confirming array-based detection of methylation at a small number of 
significant CpG loci was accomplished by quantitative methylation-specific PCR (Q-MSP) 
in at least 8 melanoma cell lines and normal human melanocytes (NHM). Q-MSP assays 
generally validated array methylation levels well (Figure S1).
In order to further query the observed associations between methylation and pathologic 
features at individual CpG sites, we interrogated The Cancer Genome Atlas (TCGA) 
database, in which methylation was assayed using the genome-wide Illumina 
HumanMethylation450 Beadchip array. We analyzed the subset of primary melanomas 
(n=66), examining methylation at CpG loci within 200 base pairs of the significant CpG loci 
from the Golden Gate array. A general decrease in methylation in association with mitotic 
rate in the region of MMP14_P208 was observed. While methylation at select individual 
CpG sites tended to increase in association with increasing Breslow thickness, methylation 
at other sites tended to decrease or remain unchanged (data not shown). Overall, the 
relationship between methylation and either Breslow thickness or BRAF mutation status was 
heterogenous (Figure S2). Primary tumors deposited in TCGA database were larger than our 
own samples, with Breslow thickness ranging from 1.92mm to 75mm, and only 5 tumors < 
4mm in Breslow thickness. In our own samples, 18 tumors had a Breslow thickness < 2mm. 
In an independent clustering analysis of TCGA melanomas, across all samples (primary and 
metastatic tumors combined), three robust methylation-based clusters were observed in 
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consensus non-negative matrix factorization (Broad Institute TCGA Data Analysis Center, 
2014a).
In our gene expression analyses, only CD40 and IRAK3 showed correlation coefficients of 
less than −0.5 between methylation and gene expression (data not shown). In correlation of 
mRNA expression and DNA methylation from TCGA database, across all tumors (primary 
and metastatic samples), there was at least one CpG site in the regulatory region of each of 
the top genes from our list except for KLK10 that showed highly significant correlation 
between methylation and gene expression (Table S1, collated from the Broad Institute 
TCGA Data Analysis Center, 2014b).
Clustering reveals a hypermethylated melanoma phenotype associated with Breslow 
thickness
We next investigated whether melanomas clustered into distinct methylation-based 
subgroups. Exploratory statistics had revealed that most of the CpGs associated with sex 
were on the X-chromosome. To avoid sex confounding, CpGs on the X-chromosome were 
removed for the purposes of clustering. Results of unsupervised hierarchical clustering on 
the remaining 1,327 CpG sites showed epigenetic heterogeneity, but many invariant CpG 
loci (Figure S3A). Therefore, we limited the analysis to the most variable CpG sites 
(standard deviation >0.25), which created a panel of 235 CpG sites. Unsupervised clustering 
on the most variable 235CpG sites, excluding the X-chromosome, identified 3 methylation 
clusters, with one cluster notably exhibiting high methylation across nearly all loci (Figure 
S3B).
K-Means clustering was applied to determine clusters more formally, using 3 clusters as 
suggested by the results from the unsupervised clustering and supported by the Dunn index. 
K-Means clustering confirmed the presence of a high-methylation subgroup (n=6, Figure 
2A). The clusters were designated as high-methylation (HM), intermediate-methylation 
(IM), and low-methylation (LM), according to the relative overall degree of methylation. 
We found that these clusters were significantly associated with Breslow thickness and 
mitotic rate (Figure 2B). Both HM and IM groups had significantly greater Breslow 
thickness than the LM group after Bonferroni correction (P = 0.048 and 0.048, respectively), 
though they were not different from each other. Several individual CpG sites, e.g. in 
HOXA9 and IRAK3, that showed increasing methylation in association with higher Breslow 
thickness (Table 2) were also among the genes significantly hypermethylated in the HM 
group vs. other tumor clusters. The IM group had the highest mitotic rate, and was 
significantly different from the LM group (Bonferroni-adjusted P = 0.016), while the HM 
group had a broad range of mitotic rates and was not statistically different. While the HM 
group approached a higher incidence of BRAF mutation and the LM group approached a 
higher absence of ulceration, neither difference was statistically significant (Bonferroni-
adjusted P = 0.232 and 0.305, respectively).
Discussion
In summary, array-wide methylation patterns revealed significant trends in association with 
multiple tumor features. There was a trend toward increased methylation with Breslow 
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thickness and the presence of BRAF mutation (vs. wildtype) array-wide. In contrast, mitotic 
rate exhibited a negative association with methylation overall. Distinct subsets of CpG sites 
were differentially methylated in association with each of these tumor features, although a 
limited number of individual CpGs were significantly associated with pathologic attributes. 
These include loci in the regulatory regions of genes involved in various functional 
pathways, including transcription factors important in embryogenesis (HOXA9), immune-
related signaling molecules (IRAK3), and putative tumor invasion enzymes (MMP14), per 
Gene Cards (Rebhan et al., 1998, www.genecards.org). Unsupervised clustering identified 
the presence of three methylation-defined subsets including a high-methylation cluster. K-
means clustering confirmed low-, intermediate-, and high-methylation melanoma clusters; 
these differed significantly in terms of Breslow thickness and mitotic rate, with the HM 
cluster exhibiting the highest mean Breslow thickness while the IM cluster was significantly 
associated with high mitotic rate.
Interestingly, despite a substantial loss of global DNA methylation content in the 
progression from benign nevus to melanoma, there is a selective acquisition of methylation 
with tumor progression (Koga et al., 2009). While our results show heterogeneity in the 
methylation patterns of primary melanomas, the markers most strongly related to prognostic 
characteristics did not overlap with the most robust CpG markers identified for melanoma 
diagnosis, most of which exhibited relative hypomethylation in melanomas rather than 
hypermethylation(Conway et al., 2011). Of the panel of markers that we have previously 
shown to best discriminate between melanomas and non-malignant nevi, only one 
(KLK10_P268_R) was identified by the present study, showing an association with BRAF 
in univariate analysis (Conway et al., 2011). BRAF mutation has been associated with both 
hypomethylation and hypermethylation of many genes in melanoma cell lines, and 
mechanisms underlying these associations have begun to be elucidated (Hou et al., 2012; 
Liu et al., 2012). However, previous studies have not found different average methylation 
levels in cell lines or primary melanomas with BRAF mutation versus wildtype(Gao et al., 
2013; Tellez et al., 2009). Using a sensitive analysis method, our study clarifies that the 
overall pattern of methylation within primary melanomas tends to be higher in tumors 
harboring mutated BRAF. We found only a weak association of methylated CpG sites with 
ulceration, consistent with a previous study (Rakosy et al., 2013). Our study also reports a 
novel association between methylation and the clinical covariates of Breslow thickness and 
mitotic rate. In addition, the presence of a cluster of primary melanomas remarkable for its 
high levels of methylation across a large number of variably-methylated CpG sites supports 
the presence of a CIMP in melanomas, confirming earlier reports based on limited numbers 
(13 and 15) of methylation markers (Tanemura et al., 2009; Tellez et al., 2009).
Our finding of three-methylation based clusters in melanoma is supported by an independent 
clustering analysis performed by the Broad Institute. The inverse association between 
methylation and mitotic rate that we observed was also supported in TCGA primary tumors. 
While the associations of methylation at specific CpG sites with Breslow thickness and 
mutated BRAF were not observed in TCGA tumors, this may be due to the difference 
between our own tumor samples, which tended to be thinner and more superficial, and the 
primary melanoma samples deposited in TCGA, most of which are tumor stage 4b. 
Furthermore, the CpG sites from the HumanMethylation450 array were not identical to the 
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CpG sites from the Golden Gate array for our top markers of interest, and methylation trends 
at individual CpG sites may not always be reflected in the neighboring region. Some 
correlation of methylation with gene expression was also evident. While the observed 
methylation differences may serve as useful biomarkers for clinically-relevant pathologic 
features, it is unclear to what extent variable degrees of methylation differences at individual 
CpG sites mediate biologic effects.
Our study reports an association of pathologic tumor characteristics with DNA methylation 
in 47 primary melanomas, based on a panel of CpG sites in the promoter regions of 793 
cancer-related genes. Our results raise the question as to whether DNA methylation plays a 
role in biological mechanisms underlying the observed clinical attributes. We found that the 
highly-methylated tumor cluster, comprising 6 of the 47 primary melanomas investigated, is 
associated with increased Breslow thickness; however, further conclusions are limited by the 
number of tumors in this cluster. Thus, the putative existence of a CIMP, whether it 
comprises high- and intermediate-methylation subgroups, and the association with mitotic 
rate remain to be elucidated in larger studies. It is unclear whether HOXA9_P303F and other 
CpG sites are associated with Breslow thickness because they mark a CIMP with poorer 
prognostic features, or whether their association with Breslow thickness is independent of a 
CIMP. Moreover, it is unknown whether CIMP represents a biologically-distinct subgroup 
or a more advanced set of tumors that has acquired additional genetic and epigenetic 
changes during melanoma progression. To our knowledge, our study includes the largest 
number of primary melanomas analyzed using a high throughput platform to investigate 
methylation patterns at scale. A limitation to our study is that the Golden Gate platform, 
which is targeted to the promoters of genes with known significance to cancer, is not 
comprehensively genome-wide, and the sites most relevant to a putative CIMP may be 
specific to melanomas, rather than universal to cancer. A genome-wide panel could be used 
in future studies to establish cut-off thresholds for defining methylation-derived subtypes 
including a melanoma (M)-CIMP. As all array-based data has certain limitations, 
sequencing approaches could also be used to complement array-based findings. We 
conclude that methylation is associated with important tumor characteristics, and that 
methylation profiles support the possibility of three melanoma subtypes including a CIMP, 
but the methylation events distinguishing these putative subtypes will need to be more fully 
characterized in a larger set of melanomas using a more comprehensive platform, along with 
thorough molecular characterization and outcome data.
Methods
Primary melanomas
Primary formalin-fixed paraffin-embedded (FFPE) invasive cutaneous melanomas (n=47) 
were obtained from the University of North Carolina (UNC) Hospitals Pathology Archives 
and the University of New Mexico (UNM) Hospitals Pathology Archives as described 
(Conway et al., 2011). Age, sex, and anatomic site were abstracted from pathology reports. 
The UNC and UNM Institutional Review Boards approved the study. Five µm-thick tissue 
sections were cut from each block containing melanoma and were mounted on uncoated 
glass slides, and a hematoxylin and eosin (H&E)-stained slide of each melanoma was 
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reviewed by an expert dermatopathologist (PG) to confirm diagnosis, classify histologic 
subtype, and score standard histopathology features. BRAF and NRAS mutations were 
determined as previously described (Thomas et al., 2004, 2007). The dermatopathologist 
also encircled the tumors on H&E slides to use as guides for manual dissection of melanoma 
cells, and DNA was prepared as previously published (Thomas et al., 2004, 2007).
Bisulfite treatment of DNA and array-based methylation analysis
Sodium bisulfite conversion and subsequent purification of DNA was performed using EZ 
DNA Methylation Gold kit (Zymo Research, Orange, CA, USA) according to the 
manufacturer’s protocol. DNA methylation profiling was accomplished using the Illumina 
Golden Gate Cancer Panel I methylation bead array (Illumina, San Diego, CA, USA) to 
simultaneously interrogate 1505 CpG loci associated with 807 cancer-related genes as 
previously described (Conway et al., 2011).
Quantitative methylation-specific polymerase chain reaction (Q-MSP)
Technical validation of IRAK3 and HOXA9 methylation was performed in cell lines, due to 
insufficient DNA remaining from primary tumors. Q-MSP was performed on the Applied 
Biosystems 7900 HT Fast Real-Time PCR System using Fast Start Universal SYBR Green 
Master Mix (Roche) with 20ng of bisulfite treated DNA, 200nm of each primer (methylated 
and unmethylated pairs recorded in Table S2) in a 25 µl reaction with the following cycling 
conditions: 95°C for 10 minutes, followed by 45 cycles of 95°C for 10 seconds and 59°C for 
25 seconds. Quantitative methylation was measured using the fluorescence-based, 
methylation-specific, real-time PCR data. The calculation of methylation % for each sample 
relative to 100% methylated control equals 2(−ΔΔCt) multiplied by 100.
Statistical methods
Methylation data were assembled in Genome Studio software (Illumina, San Diego, CA). 
The methylation level for individual CpGs was represented by the β-value, defined as 
previously described (Conway et al., 2011). Filtering was performed on a starting set of 48 
samples and 1505 CpGs. β-values of CpGs with detection p-value >10−5 were considered 
unreliable(Marsit et al., 2009). We removed 103 CpGs that had >20% unreliable β-values 
and 1 sample that had >25% unreliable β-values. The final dataset consisted of 1402 CpGs 
and 47 samples. Subsequent statistical analyses were carried out using R software (http://r-
project.org). The array data has been deposited in GEO (accession number GSE54623).
Volcano plots were derived by conducting array-wide locus by locus univariate analysis 
employing fully supervised methods to plot each pathologic attribute and BRAF mutation 
against β-values for CpG methylation at all 1402 CpG sites. We regressed y on each clinical 
covariate and plotted the regression coefficients for each clinical attribute against the 
statistical significance (negative log-p-values) of each coefficient. Scatter plots were 
constructed by showing correlation of estimated regression coefficients from Breslow 
thickness vs methylation association analysis against regression coefficients from mitotic 
rate vs methylation association analysis.
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Univariate analysis was used to compare the association between methylation and a 
pathologic covariate, adjusting for age, gender, and batch effects. In addition to age, gender, 
and batch, multivariate analysis adjusted for other pathologic covariates considered in this 
study, in order to confirm that associations between CpGs and pathologic attributes 
remained statistically significant in the presence of other covariates.
Unsupervised hierarchical clustering analysis using the Euclidean metric and complete 
linkage was utilized to visualize methylation patterns across the 47 samples on the 235 most 
variable CpGs (standard deviation > 0.25 and excluding CpGs on the X chromosome). K 
means clustering was performed to partition the samples into K=3 clusters. The number of 
clusters K was chosen based on the Dunn index (Dunn, 1973) and the hierarchical clustering 
tree structure. For the comparison of the clusters with clinical attributes, p-values were 
computed using the pairwise Wilcoxon rank sum test and adjusted by Bonferroni correction.
Validation using TCGA data
Methylation β-values from the Illumina Golden Gate Cancer Panel I methylation array were 
validated using quantitative methylation specific PCR (Q-MSP). For TCGA validation data, 
we downloaded the subset of primary melanoma samples with available methylation and 
pathologic information of interest that had been deposited in TCGA at the time of 
submission. In this dataset, methylation was assayed using the genome-wide Illumina 
HumanMethylation450 Beadchip. Methylation data from primary melanoma samples with 
recorded Breslow thickness (n = 51), mitotic rate (n = 14), and BRAF V600E or V600K (n = 
66) was extracted. Methylation beta values from all CpG loci within 500 base pairs of the 
most significant probes from the Golden Gate array (q < 0.1) were collated and plotted 
against the respective pathologic feature. All CpGs on the Infinium HumanMethylation450 
array that were located within 200 bases upstream or downstream of either the 
HOXA9_P303_F, IRAK3_P185_F, PTK7_E317, ABCB4_E429, MMP14_P208, or 
KLK10_P268 CpG sites on the Golden Gate array were included in this analysis. The 
TCGA dataset for cutaneous melanoma is open access, and data are available without 
restrictions or limitations, as per TCGA publication guidelines. Visualization of methylation 
trends and calculation of Spearman’s rank correlation coefficients were carried out in 
Microsoft Excel (2010).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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We identified an association between prognostic tumor features and DNA methylation in 
primary melanomas, based on a panel of CpG sites in 793 cancer-related genes. Our 
findings link methylation with clinically significant pathologic and molecular features in 
melanoma, raising the question of whether methylation plays a role in the biological 
mechanisms underlying the observed clinical attributes, or is related to melanoma 
progression. We report that methylation patterns in primary melanomas fall into three 
methylation-based clusters, including one cluster remarkable for its high levels of 
methylation, which lends support to the presence of a CpG island methylator phenotype 
(CIMP) in melanoma.
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Figure 1. Array-wide patterns of methylation associated with clinical characteristics
Volcano plots were utilized to display array-wide association patterns between methylation 
and a clinical covariate across all CpGs. Clinical attributes included mutation status in 
addition to three features used in the AJCC staging of melanoma: Breslow thickness, 
ulceration, and mitotic rate.
(A) Each point represents a regression coefficient for the covariate vs. methylation level at a 
particular CpG site, plotted along the x-axis. The y-axis represents statistical significance, 
with points above the dashed blue line having p-values <0.05, and the dashed red line 
illustrating the threshold for p-values <0.01.
(B) Scatter plot showing correlation of regression coefficients for Breslow thickness vs 
mitotic rate indicates that a distinct set of CpGs marks each covariate. Blue circles indicate 
CpG sites at which the coefficient for Breslow thickness had a p-value < 0.01 while the 
coefficient for mitotic rate had a p-value > 0.1. Red triangles indicate the converse.
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Figure 2. K-means clustering of most variant CpG sites identifies methylation-based subgroups 
that are associated with Breslow thickness
K-means clustering was performed to partition the samples into K= 3 clusters.
(A) If X chromosome CpGs are excluded, 235 CpGs showed high variability with SD > 
0.25. Heat map shows K means clustering of the 235 CpGs with the largest variance across 
all 47 primary melanoma samples, with K = 3 based on the unsupervised clustering results. 
Samples are in columns and CpG sites are in rows. Red indicates methylated, green 
indicates unmethylated.
(B) Clinical attributes are plotted against the 3 subgroups defined by K-means clustering. 
Dark lines = medians. Pairwise comparison showed that both medium- and high-methylation 
clusters were significantly associated with Breslow thickness, while the medium cluster was 
significantly associated with mitotic rate (*Bonferroni-adjusted P < 0.05).
Thomas et al. Page 14











































Thomas et al. Page 15
Table 1
Overall demographics along with clinical and histologic characteristics of 47 primary melanomas evaluated 





  Male 23 (49)
  Female 24 (51)
Age
  Median (range) 56 (38–72)
Anatomic site
  Head/neck 12 (26)
  Trunk 19 (40)
  Extremity 16 (34)
Melanoma histologic subtype
  SSM 23 (49)
  NM 5 (11)
  LMM 5 (11)
  ALM 5 (11)
  UNCL, SC 9 (19)
Breslow thickness (mm)
  Median (range) 3.1 (0.4–15.0)
Ulceration
  Absent 28 (60)
  Present 18 (38)
Indeterminant 1 (2)
Mitoses
  Median (range) 1.0 (0–9.0)
Mutation
  Wildtype 22 (47)
  BRAF 20 (43)
  NRAS 5 (11)
Abbreviations: SSM; superficial spreading melanoma, LMM; lentigo maligna melanoma, NM; nodular melanoma, ALM; acral lentiginous 
melanoma, SC; spindle cell melanoma, UNCL; unclassifiable melanoma, na; not applicable.
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Table 2
CpG sites Differentially Methylated in Association with Pathologic Characteristics, P-value < 0.001
Breslow Thickness
Probe ID Univariate1 Multivariate3 Pearson Coefficient3
HOXA9_P303_F* 4.68E-05* 2.74E-05 .609+
PTK7_E317_F* 0.000115* 0.000186 .434
ABCB4_E429_F* 0.000151* 0.000192 .371
IRAK3_P185_F* 0.000157 0.000319 .507
GNG7_E310_R 0.00036 0.000582 .238+
HOXA9_E252_R 0.000588 0.00094 .530
RUNX1T1_E145_R 0.000767 0.001953 .277
Mitotic Rate
Probe ID Univariate Multivariate Pearson Coefficient
+ USP29_P282_R 0.00086 0.000272 −.476
MMP14_P208_R 0.017198* 6.33E-05 −.265
SEMA3A_P658_R 0.013546 0.000228 −.272
AATK_P709_R 0.038656 0.000293 −.0825
UGT1A7_P751_R 0.017396 0.000551 −.453
SHH_P104_R 0.006076 0.000566 −.281
Ulceration




MAP3K1_P7_F 0.000964 0.005689 0.717439 0.378613
BRAF Mutation4 vs. Wildtype




+ KLK10_P268_R * 3.14E-05 0.000294 0.523963 0.220489
CD40_E58_R 0.000747 0.00028 0.470448 0.17565
DNMT3B_P352_R 0.001091 0.000612 0.254696 0.122829
+ SEMA3B_P110_R 0.001328 0.000895 0.554509 0.259127
1
Univariate analyses were conducted using linear models on logit transformed β methylation values to assess the association between methylation 
(outcome) and each clinical covariate (predictor), adjusting for age, gender, and batch.
2
Multivariate analyses were further performed to assess if the association remained significant in the presence of other clinical covariates.
3
Pearson correlation of raw β-value (non-logit transformed) reported. Similarly, raw mean β-value differences are reported.
4
BRAF mutation compared to wildtype only; NRAS positive tumors (n=5) excluded.
*
when adjusted for false discovery rate, q-value < 0.1
+
previously published as significantly differentially methylated between melanomas and benign nevi (Conway et al., 2011)
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